Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Cantor Fitzgerald sets price target on Skye Bioscience shares

EditorAhmed Abdulazez Abdulkadir
Published 2024-05-23, 07:00 a/m
SKYE
-

On Thursday, Cantor Fitzgerald began coverage on Skye Bioscience Inc. (NASDAQ:SKYE), assigning an Overweight rating and setting a price target of $21.00 for the company's stock. The firm's analysis highlighted Skye Bioscience's promising pipeline, which focuses on modulating the cannabinoid receptor 1 (CB1) with two lead assets in development.

Skye Bioscience is gearing up for a significant period in its clinical development timeline. The company has announced plans to commence a Phase 2 trial for nimacimab, a peripheral CB1 receptor inhibitor aimed at treating obesity, in the third quarter of 2024. Additionally, Skye is expected to release top line data from the Phase 2a trial of SBI-100 Ophthalmic Emulsion (OE), a CB1 receptor activator for glaucoma treatment, in the second quarter of 2024.

The initiation of the Overweight rating reflects the firm's confidence in Skye Bioscience's potential within the biopharmaceutical sector. The $21.00 price target suggests that Cantor Fitzgerald sees significant upside from the current trading levels of Skye Bioscience's shares.

Investors are keeping a close eye on Skye Bioscience as the company progresses through its clinical trials. The outcomes of these trials could have a substantial impact on the company's future and its position in the market for treatments targeting the CB1 receptor.

The company's strategic focus on leveraging cannabinoid receptor modulation for therapeutic purposes is part of a broader trend in the pharmaceutical industry to explore novel treatment avenues. Skye Bioscience's advancements in this area are particularly noteworthy as they push forward to potentially address unmet medical needs in obesity and glaucoma.

InvestingPro Insights

As Skye Bioscience Inc. advances through critical phases of its clinical trials, investors considering the company's potential should be aware of its financial health and market performance. According to InvestingPro data, Skye Bioscience holds a Price to Book ratio of 4.32 as of the last twelve months leading up to Q1 2024, which may interest those evaluating company assets versus market valuation. Despite challenges reflected by an Operating Income of -$16.57M USD and an EBITDA of -$16.45M USD, the company has shown a strong return over the last three months, with a 66.39% price total return.

InvestingPro Tips suggest that Skye Bioscience has more liquid assets than short-term obligations, which could provide some financial flexibility in its operations. Furthermore, the company's stock has experienced large price upticks, with an impressive six-month price total return of 688.16%. While analysts do not anticipate Skye Bioscience will be profitable this year, the high return over the last year of 211.17% might be an indicator of strong investor optimism surrounding its clinical developments.

For those seeking a deeper dive into Skye Bioscience's financials and market performance, InvestingPro offers additional insights and metrics. To make the most of these resources, use the coupon code PRONEWS24 for an additional 10% off a yearly or biyearly Pro and Pro+ subscription. With 9 more InvestingPro Tips available, investors can gain a comprehensive understanding of Skye Bioscience's investment profile.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.